NASDAQ
12.12.25 | 21:59
11,900 US-Dollar
-3,88 % -0,480
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting | 15 | GlobeNewswire (USA) | ||
| Mo | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.12. | Cullinan Therapeutics Announces Fast Track Designation For CLN-049 | 2 | RTTNews | ||
| CULLINAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.12. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia | 156 | GlobeNewswire (Europe) | Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01... ► Artikel lesen | |
| 26.11. | Cullinan Oncology stock price target raised to $36 at Jones Trading | 2 | Investing.com | ||
| 25.11. | Vielversprechende AML-Daten: BTIG erhöht Kursziel für Cullinan Oncology auf 38 US-Dollar | 12 | Investing.com Deutsch | ||
| 25.11. | Cullinan Oncology stock price target raised to $38 at BTIG on promising AML data | 2 | Investing.com | ||
| 21.11. | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11. | H.C. Wainwright raises Cullinan Oncology stock price target on NDA progress | 4 | Investing.com | ||
| 21.11. | Fortschritte bei Zipalertinib-Zulassung: H.C. Wainwright hebt Kursziel für Cullinan Oncology an | 12 | Investing.com Deutsch | ||
| 20.11. | Cullinan Therapeutics rises on rolling submission for zipalertinib | 1 | Seeking Alpha | ||
| 06.11. | Cullinan Therapeutics GAAP EPS of -$0.77 | 3 | Seeking Alpha | ||
| 06.11. | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 03.11. | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.10. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025 | 269 | GlobeNewswire (Europe) | CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM),... ► Artikel lesen | |
| 13.10. | Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations | 1 | Benzinga.com | ||
| 12.09. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum | 3 | GlobeNewswire (USA) | ||
| 05.09. | H.C. Wainwright reiterates Buy rating on Cullinan Oncology stock at $24 | 3 | Investing.com | ||
| 04.09. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MICROBOT MEDICAL | 2,150 | +4,47 % | Microbot Medical Inc.: Microbot Medical Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio | Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,690 | -1,23 % | Voyager Therapeutics (VYGR): Strong Q3 Prompts Bullish Coverage | ||
| ONCOLYTICS BIOTECH | 1,000 | +0,15 % | Oncolytics Biotech reschedules shareholder vote on U.S. domicile move | ||
| ABEONA THERAPEUTICS | 4,560 | 0,00 % | Abeona Therapeutics Inc.: Abeona Therapeutics Announces First Patient Treatment with ZEVASKYN Gene Therapy | CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a... ► Artikel lesen | |
| ADICET BIO | 0,420 | -0,90 % | MaxCyte, Inc: MaxCyte Signs Platform License Agreement with Adicet Bio | MaxCyte's Flow Electroporation® technology and ExPERT platform to support development of Adicet's gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,250 | +3,31 % | H.C. Wainwright bestätigt Kaufempfehlung für Marker Therapeutics mit über 650 % Kurspotenzial | ||
| KALVISTA PHARMACEUTICALS | 14,100 | -2,08 % | KalVista, Health Catalyst, Bio-Techne Lead After-Hours Gains On Earnings Updates | LONDON (dpa-AFX) - Several healthcare and biotech stocks posted notable gains in Monday's after-hours trading following earnings updates and guidance revisions.KalVista Pharmaceuticals Inc.... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 6,850 | +9,60 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grant | FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen | |
| QUANTUM-SI | 1,290 | -7,86 % | Quantum-Si stock rating reiterated by H.C. Wainwright on Proteus potential | ||
| PROTARA THERAPEUTICS | 4,880 | +0,41 % | Protara therapeutics raises $75 million in public offering | ||
| SAGIMET BIOSCIENCES | 5,500 | +2,80 % | Sagimet Biosciences Inc.: Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration | SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic... ► Artikel lesen | |
| CRINETICS PHARMACEUTICALS | 41,600 | -3,26 % | Crinetics Pharmaceuticals, Inc.: Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) | Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAHSAN DIEGO, Dec. 11, 2025(Nasdaq: CRNX) today announced that... ► Artikel lesen | |
| MEIRAGTX | 7,300 | -3,95 % | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results | Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment... ► Artikel lesen | |
| NURIX THERAPEUTICS | 19,070 | 0,00 % | Cathie Wood's ARK sells Iridium stock, buys Nurix on Wednesday | ||
| RAPPORT THERAPEUTICS | 30,295 | +5,26 % | H.C. Wainwright raises Rapport Therapeutics stock price target to $40 on strong seizure drug data |
CULLINAN THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 11,900 Euro und damit -3,88 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CULLINAN THERAPEUTICS INC finden Sie auf Wallstreet Online.